|
|
|
|
|
|
|
|
|
|
|
|
|
27.01.26 - 08:57
|
BASF Aktie vor dem Ausbruch? Chartanalyse (Aktiencheck)
|
|
|
Zürich (www.aktiencheck.de) - BASF-Chartanalyse der UBS:
Nach dem Rücksetzer vom Freitag (-0,9%) hat die Aktie der BASF SE (ISIN: DE000BASF111, WKN: BASF11, Ticker-Symbol: BAS, NASDAQ OTC-Symbol: BFFAF) zum gestrigen Wochenstart 0,5% auf 46,34 EUR zugelegt, wie aus der Veröffentlichung "KeyInvest DailyTrader" der UBS hervorgeht. [mehr]...
|
|
|
|
|
26.01.26 - 14:03
|
Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Charles (Charlie) Fuchs, M.D., M.P.H., as Senior Advisor.
Dr. Fuchs brings extensive experience as an innovator and executive leader spanning oncology, immunology, and translational medicine, with a proven track record of advancing programs through global product development and regulatory approvals. Most recently, Dr. Fuchs served as Senior Vice President and Global Head of Product Development for Oncology and Hematology at Roche, where he led the development and execution of a new, comprehensive global strategy for Roche's Oncology and Hematology division. In this role, Dr. Fuchs drove portfolio growth, oversaw the approval of multiple new therapies and indications across cancer and blood disorders, and led the strategic acquisition of external assets to strengthen the division's portfolio.
“Dr. Fuchs brings a depth of experience acros...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
